Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis

被引:32
作者
Reinhorn, Daniel [1 ]
Mutai, Raz [1 ]
Yerushalmi, Rinat [1 ,2 ]
Moore, Assaf [1 ,2 ]
Amir, Eitan [3 ]
Goldvaser, Hadar [4 ,5 ]
机构
[1] Rabin Med Ctr, Inst Oncol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Shaare Zedek Med Ctr, Oncol Inst, Jerusalem, Israel
[5] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
关键词
Breast cancer; de novo metastatic; Surgery; Locoregional treatment; Survival; LONG-TERM SURVIVAL; PRIMARY TUMOR; SURGICAL RESECTION; OPEN-LABEL; SURGERY; IMPACT; TRASTUZUMAB; SUBTYPES; OUTCOMES;
D O I
10.1016/j.breast.2021.05.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Locoregional therapy (LRT) in de novo metastatic disease is controversial with inconsistent results from randomized control trials (RCTs). Methods: RCTs comparing LRT and systemic therapy to standard therapy alone in de novo metastatic breast cancer were identified. Hazard ratios (HRs) and their associated 95% confidence intervals (CIs) were computed and pooled in a meta-analysis using generic inverse variance. Overall survival (OS) and time to locoregional progression data were extracted for the intention to treat (ITT) population. Data on OS for pre-specified subgroups defined by tumor subtype and by site of metastases were also extracted. Results: Analyses included 4 trials comprising 970 patients. LRT included standard surgery to the primary breast tumor in all studies, and adjuvant radiation per standard of care was required in 3 studies. Compared to standard treatment, LRT was not associated with improved OS in the ITT population (HR 0.97, 95% CI 0.72-1.29, p = 0.81). However, LRT was associated with improved time to locoregional progression (HR 0.36, 95% CI 0.14-0.95, p = 0.04). LRT was not associated with improved OS in any tumor subtypes, including hormone receptor positive (HR 0.96, 95% CI 0.65-1.43), triple negative (HR 1.4, 95% CI 0.50-3.91) and human epidermal growth factor receptor 2 positive disease (HR 0.93, 95% CI 0.68-1.28). Additionally, LRT did not improve OS in bone only disease (HR 0.97, 95% CI 0.58-1.62) and in visceral disease (HR = 1.02, 95% CI 0.77-1.35). Our critical appraisal has identified some methodological problems in the design and conduct of the studies included that could affect the meta-analysis result. Conclusions: LRT in de novo metastatic breast cancer is not associated with improved OS. Results are consistent among different breast cancer subgroups. However, this conclusion should be interpreted with caution in view of the limitations identified in meta-analysis. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:173 / 181
页数:9
相关论文
共 39 条
[1]   Surgical Injury Enhances the Expression of Genes That Mediate Breast Cancer Metastasis to the Lung [J].
Al-Sahaf, Osama ;
Wang, Jiang Huai ;
Browne, Tara J. ;
Cotter, Tom G. ;
Redmond, H. Paul .
ANNALS OF SURGERY, 2010, 252 (06) :1037-1043
[2]   Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis [J].
Amadeo Leone, Bernardo ;
Teodoro Vallejo, Carlos ;
Omar Romero, Alberto ;
Raul Machiavelli, Mario ;
Eduardo Perez, Juan ;
Leone, Julieta ;
Leone, Jose Pablo .
BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) :537-548
[3]   Surgery and survival in patients with stage IV breast cancer [J].
Arciero, Cletus ;
Liu, Yuan ;
Gillespie, Theresa ;
Subhedar, Preeti .
BREAST JOURNAL, 2019, 25 (04) :644-653
[4]   Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial [J].
Badwe, Rajendra ;
Hawaldar, Rohini ;
Nair, Nita ;
Kaushik, Rucha ;
Parmar, Vani ;
Siddique, Shabina ;
Budrukkar, Ashwini ;
Mittra, Indraneel ;
Gupta, Sudeep .
LANCET ONCOLOGY, 2015, 16 (13) :1380-1388
[5]   What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? [J].
Barrios, C. H. ;
Sampaio, C. ;
Vinholes, J. ;
Caponero, R. .
ANNALS OF ONCOLOGY, 2009, 20 (07) :1157-1162
[6]   INDEXES AND BOUNDARIES FOR QUANTITATIVE SIGNIFICANCE IN STATISTICAL DECISIONS [J].
BURNAND, B ;
KERNAN, WN ;
FEINSTEIN, AR .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1990, 43 (12) :1273-1284
[7]   Matched Pair Analyses of Stage IV Breast Cancer with or Without Resection of Primary Breast Site [J].
Cady, B. ;
Nathan, N. R. ;
Michaelson, J. S. ;
Golshan, M. ;
Smith, B. L. .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (12) :3384-3395
[8]   Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review [J].
Caswell-Jin, Jennifer L. ;
Plevritis, Sylvia K. ;
Tian, Lu ;
Cadham, Christopher J. ;
Xu, Cong ;
Stout, Natasha K. ;
Sledge, George W. ;
Mandelblatt, Jeanne S. ;
Kurian, Allison W. .
JNCI CANCER SPECTRUM, 2018, 2 (04)
[9]   Surgery, wound healing, and metastasis: Recent insights and clinical implications [J].
Ceelen, Wim ;
Pattyn, Piet ;
Mareel, Marc .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 89 (01) :16-26
[10]   The impact of new chemotherapeutic and agents on survival in a population-based of women with metastatic breast cancer hormone cohort [J].
Chia, Stephen K. ;
Speers, Caroline H. ;
D'yachkova, Yulia ;
Kang, Anna ;
Malfair-Taylor, Suzanne ;
Barnett, Jeff ;
Coldman, Andy ;
Gelmon, Karen A. ;
O'Reilly, Susan E. ;
Olivotto, Ivo A. .
CANCER, 2007, 110 (05) :973-979